Biologic Therapy Market Trends

ID: MRFR/HC/0344-CR

200 Pages

Rahul Gotadki

July 2025

Biologic Therapy Market Research Report By Therapy Type (Monoclonal Antibodies, Vaccines, Cell Therapy, Gene Therapy), By Application (Oncology, Autoimmune Diseases, Infectious Diseases, Cardiovascular Diseases), By Route of Administration (Intravenous, Subcutaneous, Intramuscular), By End-user (Hospitals, Clinics, Home Healthcare), and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Forecast to 2035

Request Free Sample

Summary Table of Contents Segmentation Download PDF

Market Trends

Key Emerging Trends in the Biologic Therapy Market

The biologic therapy market is present in the process of big ameliorations, pushed by improvements in biotechnology, the growing occurrence of continual diseases, and a growing consciousness of customized medicine. This dynamic quarter is witnessing several key developments which are reshaping the landscape of biologic treatment options and their programs within the field of healthcare. The rise of biosimilars is a full-size trend shaping the biologic therapy landscape. As patents for numerous original biologics expire, biosimilar alternatives are coming into the market, presenting powerful alternatives. This is fostering competition, reducing treatment costs, and increasing accessibility to biologic healing procedures, mainly in rising markets. Innovations in bioprocessing and production technologies are optimizing the production of biologics. Continuous manufacturing, single-use structures, and different advancements are enhancing efficiency, scalability, and fee effectiveness, thereby addressing demanding situations related to the excessive fees and complexities associated with biologic manufacturing. Immunotherapy is rising as a dominant trend within biologic therapy, mainly inside the treatment of most cancers. Therapies, along with immune checkpoint inhibitors and chimeric antigen receptor (CAR) T-cell treatments, are revolutionizing cancer remedies by harnessing the body's immune gadget to target and put off most cancer cells. The biologic therapy marketplace is witnessing a shift toward patient-centric drug delivery techniques. Innovations in drug shipping technologies, which include subcutaneous and intramuscular injections, wearable devices, and oral formulations, aim to enhance the affected person's convenience, compliance, and normal treatment. These improvements are especially crucial in persistent conditions that require long-term biological therapy. Regulatory bodies are adapting to the unique characteristics of biologic remedies. There is an increasing focus on establishing clear hints for the development, approval, and up-market surveillance of biologics. This evolving regulatory landscape seeks to ensure the safety, efficacy, and niceness of biologic treatments while facilitating timely marketplace admission. Collaborations between pharmaceutical companies, biotechnology corporations, and study institutions have become more accepted within the biologic therapy marketplace. These partnerships leverage complementary expertise, resources, and networks to accelerate research and development, enhance product pipelines, and address complex healthcare challenges. The global attain of biologic treatment plans is increasing, with increasing adoption in each developed and developing region. Improving healthcare infrastructure, increasing attention, and increasing patient demand for superior treatment options are riding marketplace penetration globally.

Market Highlights

Author

Rahul Gotadki

Assistant Manager

He holds an experience of about 7+ years in Market Research and Business Consulting, working under the spectrum of Life Sciences and Healthcare domains. Rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. His expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. In addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives

Get In Touch

FAQs

What is the current valuation of the Biologic Therapy Market as of 2024?

The Biologic Therapy Market was valued at 308.65 USD Billion in 2024.

What is the projected market valuation for the Biologic Therapy Market in 2035?

The market is projected to reach 450.14 USD Billion by 2035.

What is the expected CAGR for the Biologic Therapy Market during the forecast period 2025 - 2035?

The expected CAGR for the Biologic Therapy Market during 2025 - 2035 is 3.49%.

Which segment of the Biologic Therapy Market is expected to have the highest valuation in 2035?

Monoclonal Antibodies are anticipated to reach a valuation of 170.0 USD Billion by 2035.

How do the valuations of different applications in the Biologic Therapy Market compare for 2024?

In 2024, Oncology was valued at 80.0 USD Billion, while Cardiovascular Diseases reached 108.65 USD Billion.

What are the projected valuations for the route of administration segments by 2035?

By 2035, Intravenous administration is expected to reach 170.0 USD Billion.

Which key players are leading the Biologic Therapy Market?

Key players include AbbVie, Amgen, Roche, Johnson & Johnson, and Novartis.

What is the expected growth in the Cell Therapy segment from 2024 to 2035?

The Cell Therapy segment is projected to grow from 60.0 USD Billion in 2024 to 90.0 USD Billion by 2035.

How does the Home Healthcare segment compare to other end-user segments in 2035?

Home Healthcare is expected to reach 170.14 USD Billion, indicating strong growth compared to Clinics and Hospitals.

What is the anticipated valuation for the Vaccines segment by 2035?

The Vaccines segment is projected to reach 110.0 USD Billion by 2035.

1. Market Overview

2. Market Trends

3. Market Segment Insights

4. Key Players and Competitive Insights

5. Industry Developments

6. Market Segmentation

7. Report Scope

8. Market Highlights

9. FAQs

Customize Report

Certified Researchers

Market Summary

As per MRFR analysis, the Biologic Therapy Market Size was estimated at 308.65 USD Billion in 2024. The Biologic Therapy industry is projected to grow from 319.42 USD Billion in 2025 to 450.14 USD Billion by 2035, exhibiting a compound annual growth rate (CAGR) of 3.49 during the forecast period 2025 - 2035.

Key Market Trends & Highlights

The Biologic Therapy Market is experiencing robust growth driven by innovation and increasing demand for targeted treatments.

The rise of personalized medicine is reshaping treatment paradigms across various therapeutic areas. North America remains the largest market, while the Asia-Pacific region is emerging as the fastest-growing market for biologic therapies. Monoclonal antibodies dominate the market, whereas cell therapy is witnessing the fastest growth due to its potential in treating complex diseases. The growing prevalence of chronic diseases and advancements in biotechnology are key drivers propelling market expansion.

Biologic Therapy Market

CAGR

3.49%

Market Size & Forecast

2024 Market Size	308.65 (USD Billion)
2035 Market Size	450.14 (USD Billion)
CAGR (2025 - 2035)	3.49%
Largest Regional Market Share in 2024	North America

Major Players

AbbVie (US), Amgen (US), Roche (CH), Johnson & Johnson (US), Novartis (CH), Pfizer (US), Bristol-Myers Squibb (US), Sanofi (FR), Gilead Sciences (US), Merck & Co. (US)

Market Trends

The Biologic Therapy Market is currently experiencing a dynamic evolution, driven by advancements in biotechnology and an increasing understanding of complex diseases. This sector encompasses a range of therapeutic agents derived from living organisms, which are utilized to treat various conditions, including autoimmune disorders, cancers, and infectious diseases. The growing prevalence of chronic illnesses and the demand for personalized medicine are propelling the development of innovative biologics. Furthermore, regulatory frameworks are adapting to facilitate the approval of new therapies, which may enhance market accessibility and foster competition among manufacturers. In addition, the Biologic Therapy Market is witnessing a surge in investment from both public and private sectors, indicating a robust interest in research and development. Collaborations between pharmaceutical companies and academic institutions are becoming more common, potentially leading to breakthroughs in treatment options. The rise of biosimilars is also noteworthy, as these products offer cost-effective alternatives to original biologics, thereby expanding patient access. Overall, the landscape of the Biologic Therapy Market appears poised for continued growth, with numerous opportunities for innovation and expansion in the coming years.

Rise of Personalized Medicine

The trend towards personalized medicine is gaining momentum within the Biologic Therapy Market. Tailoring treatments to individual patient profiles enhances efficacy and minimizes adverse effects. This approach is particularly relevant in oncology and autoimmune diseases, where genetic and molecular profiling can guide therapy selection.

Expansion of Biosimilars

The emergence of biosimilars is reshaping the Biologic Therapy Market by providing more affordable treatment options. As patents for original biologics expire, biosimilars offer similar therapeutic benefits at reduced costs, potentially increasing patient access and fostering competition among manufacturers.

Increased Investment in R&D

Investment in research and development is intensifying within the Biologic Therapy Market. Both public and private sectors are channeling resources into innovative biologics, driven by the need for novel therapies to address unmet medical needs. Collaborations between industry and academia are likely to yield significant advancements.

Biologic Therapy Market Market Drivers

Advancements in Biotechnology

Technological advancements in biotechnology are propelling the Biologic Therapy Market forward. Innovations in genetic engineering, monoclonal antibody production, and cell-based therapies are enhancing the efficacy and safety profiles of biologic drugs. The development of novel biologics, including CAR-T cell therapies and gene therapies, showcases the potential for groundbreaking treatments. Market data suggests that the biotechnology sector is experiencing robust growth, with investments in research and development reaching new heights. This influx of innovation is likely to drive the Biologic Therapy Market, as new therapies emerge to address unmet medical needs and improve patient outcomes.

Increasing Healthcare Expenditure

Rising healthcare expenditure across various regions is a significant driver of the Biologic Therapy Market. As countries allocate more resources to healthcare, there is a corresponding increase in the availability and accessibility of advanced therapies, including biologics. This trend is particularly pronounced in developed economies, where healthcare budgets are expanding to accommodate innovative treatments. Market Research Future suggest that the growth in healthcare spending is likely to continue, providing a favorable environment for the Biologic Therapy Market. As more patients gain access to biologic therapies, the market is expected to experience robust growth, reflecting the increasing prioritization of advanced medical solutions.

Rising Demand for Targeted Therapies

The shift towards targeted therapies is reshaping the landscape of the Biologic Therapy Market. Patients and healthcare providers are increasingly favoring treatments that specifically target disease mechanisms, leading to improved efficacy and reduced side effects. This trend is particularly evident in oncology, where targeted biologics are becoming the standard of care for various cancers. Market data indicates that the demand for targeted therapies is expected to grow significantly, driven by advancements in precision medicine. As the Biologic Therapy Market adapts to this demand, it is likely to see a proliferation of new products designed to meet the needs of patients seeking personalized treatment options.

Growing Prevalence of Chronic Diseases

The increasing incidence of chronic diseases such as rheumatoid arthritis, psoriasis, and inflammatory bowel disease is a primary driver of the Biologic Therapy Market. As these conditions become more prevalent, the demand for effective treatment options rises. According to recent data, the prevalence of autoimmune diseases has been steadily increasing, leading to a surge in the utilization of biologic therapies. This trend is expected to continue, with projections indicating that the market for biologic therapies could reach substantial figures in the coming years. The Biologic Therapy Market is thus positioned to expand significantly as healthcare providers seek innovative solutions to manage these complex diseases.

Regulatory Support and Streamlined Approval Processes

Regulatory agencies are increasingly supporting the development of biologic therapies, which is a crucial factor for the Biologic Therapy Market. Initiatives aimed at expediting the approval process for biologics, such as the FDA's Breakthrough Therapy designation, are encouraging pharmaceutical companies to invest in biologic research. This regulatory environment fosters innovation and allows for faster access to new therapies for patients. Market analysis indicates that the number of biologics receiving approval has been on the rise, reflecting a favorable trend for the Biologic Therapy Market. As regulatory pathways become more efficient, the market is likely to witness accelerated growth.

Market Segment Insights

By Type: Monoclonal Antibodies (Largest) vs. Cell Therapy (Fastest-Growing)

In the Biologic Therapy Market, <a href="https://www.marketresearchfuture.com/reports/monoclonal-antibody-therapy-market-2089">Monoclonal Antibodies</a> constitute the largest segment, showcasing a dominant presence due to their established efficacy and wide-ranging applications in treating various diseases, especially cancers and autoimmune disorders. Vaccines and <a href="https://www.marketresearchfuture.com/reports/gene-therapy-market-8399">Gene Therapy</a> also play significant roles, contributing to market dynamics as they cater to preventive and advanced therapeutic needs. The competitive landscape is further shaped by innovations and increasing investments in these two segments.

Monoclonal Antibodies (Dominant) vs. Cell Therapy (Emerging)

Monoclonal Antibodies continue to hold a dominant position in the Biologic Therapy Market due to their proven effectiveness and versatility in treating diverse conditions such as cancer and rheumatoid arthritis. Their widespread use has led to significant advancements in therapeutic strategies and patient outcomes. On the other hand, <a href="https://www.marketresearchfuture.com/reports/cell-therapy-market-5066">Cell Therapy</a> is emerging rapidly, driven by advancements in regenerative medicine and personalized treatment approaches. This segment is characterized by its potential to restore or replace damaged tissues, supported by a robust pipeline of clinical trials aiming to harness the body's natural healing processes.

By Application: Oncology (Largest) vs. Autoimmune Diseases (Fastest-Growing)

In the Biologic Therapy Market, Oncology occupies a significant portion of the market share, reflecting the high demand for innovative treatments targeting various cancer types. In contrast, the Autoimmune Diseases segment is rapidly gaining traction among healthcare providers and patients alike, indicating a growing prevalence and the need for effective therapies. Infectious Diseases and Cardiovascular Diseases, while important, continue to follow these primary segments in market influence, showcasing a diverse application landscape. The growth trends in this market are driven by increasing investments in biotechnology and advancements in research, particularly for complex diseases like cancer and autoimmune disorders. The rise in R&D activities has facilitated the development of targeted biologic therapies, enhancing treatment efficacy and patient outcomes. Additionally, the rising incidence of autoimmune diseases is creating opportunities for faster drug development and approval, solidifying the Autoimmune Diseases segment's position as a rising star in the market.

Oncology (Dominant) vs. Autoimmune Diseases (Emerging)

Oncology therapeutics remain the dominant force in the Biologic Therapy Market, benefiting from extensive research and government initiatives aimed at combating cancer. The development pipeline for cancer therapies is robust, with a focus on personalized medicine that tailor treatments to individual genetic profiles. This prevalent segment is characterized by a wide array of biologic products, including monoclonal antibodies and checkpoint inhibitors, which have revolutionized treatment paradigms. Conversely, the Autoimmune Diseases segment is emerging as a formidable competitor, characterized by a surge in clinical trials and innovative biologic drugs targeting conditions like rheumatoid arthritis and psoriasis. The growing awareness and d demand for effective treatments are establishing this segment as a key player, with an increasing number of therapies entering the market to address unmet medical needs.

By Route of Administration: Intravenous (Largest) vs. Subcutaneous (Fastest-Growing)

In the Biologic Therapy Market, intravenous (IV) administration holds the largest market share, favored for its rapid delivery and effectiveness in treating complex diseases. Subcutaneous administration is gaining traction as it offers an alternative that is less invasive and allows for at-home injections, appealing to both patients and providers alike. Intramuscular (IM) delivery maintains a presence; however, it lags in market share compared to the more prominent IV and emerging subcutaneous options.

Administration: Intravenous (Dominant) vs. Subcutaneous (Emerging)

Intravenous administration stands as the dominant route in the Biologic Therapy Market due to its established efficacy in delivering high-concentration biologics directly into the bloodstream. This method is generally preferred for acute treatments and medications requiring immediate therapeutic effects. Conversely, subcutaneous administration is emerging as a competitive alternative, especially in chronic conditions wherein patient convenience and comfort are prioritized. This route enables slower absorption and is increasingly designed for self-administration, enhancing patient adherence to therapy regimes. Both routes are essential, but the shift towards subcutaneous methods indicates a growing consumer demand for flexibility and reduced healthcare visits.

By End-user: Hospitals (Largest) vs. Home Healthcare (Fastest-Growing)

In the Biologic Therapy Market, hospitals account for the largest share among the end-user segments. They play a crucial role in administering advanced biologic treatments, leveraging their infrastructure and specialized personnel. Conversely, home healthcare has emerged as a significant player, capturing attention due to its accessibility and the growing preference for in-home treatment solutions. This segment caters to patients seeking personalized care in familiar environments, helping to drive its increasing share in the market.

Hospitals (Dominant) vs. Clinics (Emerging)

In the Biologic Therapy Market, hospitals are dominant end-users due to their comprehensive resources and ability to manage complex biologic therapies. They provide both inpatient and outpatient services, making them a primary choice for patients requiring intensive treatment. On the other hand, clinics are seen as an emerging segment, capitalizing on the trend towards decentralized care. While they generally offer less comprehensive services than hospitals, clinics provide vital outpatient care and access to biologic therapies, appealing to patients who favor convenience and lower costs. This dynamic creates a complementary relationship between hospitals and clinics as they serve distinct but overlapping patient needs.

Get more detailed insights about Biologic Therapy Market Research Report- Global Forecast to 2035

Regional Insights

In the Biologic Therapy Market, the regional segment showcased substantial market dynamics. By 2024, the North America region held a significant valuation of 130.0 USD Billion, leading the market and reflecting its advanced healthcare infrastructure and research capabilities.

Europe followed closely with a valuation of 81.0 USD Billion, notable for its strong regulatory framework and innovative biotech initiatives. The Asia Pacific region, valued at 58.0 USD Billion, was marked by rapid growth in emerging markets and increasing healthcare spending, which positioned it as a rapidly expanding sector.

South America, valued at 23.0 USD Billion, and the Middle East and Africa, with a valuation of 16.65 USD Billion, faced unique challenges such as regulatory hurdles but are gradually advancing in biologic adoption due to evolving healthcare frameworks.

Each region contributed to the Biologic Therapy Market statistics, with North America showing majority holding that dominated due to the prevalence of chronic diseases and greater access to biologic therapies, while Europe stood out by driving stringent standards and collaborations.

Overall, these regional valuations emphasized the significant role each played in shaping market growth and dynamics through unique offerings and challenges.

Biologic Therapy Market Regional Insights

Source: Primary Research, Secondary Research, Market Research Future Database and Analyst Review

Key Players and Competitive Insights

The Biologic Therapy Market has seen considerable growth over recent years, driven by the increasing prevalence of chronic diseases and a rising demand for innovative treatment options.

This market is characterized by the development of biopharmaceuticals, which are derived from living organisms and have proven highly effective in treating a variety of conditions, including autoimmune diseases, cancers, and infectious diseases.

As the industry evolves, competition has intensified, with numerous pharmaceutical companies investing heavily in research and development to create new biologic therapies. The landscape includes a mix of established players and emerging biotech firms,

all aiming to capture market share through innovative product offerings, strategic partnerships, and extensive clinical trials. Companies in this sector are focused on improving patient outcomes, enhancing treatment accessibility, and addressing unmet medical needs, which further fuels competitive dynamics within the market.

Merck & Co. has established itself as a significant player in the Biologic Therapy Market, leveraging its strong pipeline of innovative therapies and a well-developed distribution network. The company has a robust portfolio of biologic medications that cater to various therapeutic areas, showcasing its commitment to advancing healthcare.

Its strengths lie not only in the efficacy and safety of its products but also in its considerable investments in research and development, which have propelled the company to the forefront of biologic innovation. Merck & Co.'s strategic collaborations with academic institutions and other biopharma companies further enhance its market presence,

allowing the company to stay ahead in the highly competitive landscape. Additionally, its global reach enables Merck & Co. to adapt its strategies across different markets, ensuring that its biologic therapies meet the diverse needs of patients worldwide.

Novartis is another key competitor in the Biologic Therapy Market, recognized for its extensive product line and strong focus on research and development. The company has a diverse range of biologics aimed at treating various diseases, including oncology, immunology, and ophthalmology.

Novartis's strengths include its commitment to innovation and high-quality manufacturing standards, which are critical in the biologic sector where precision is paramount. The company has been active in strategic mergers and acquisitions to enhance its capabilities and expand its portfolio, successfully integrating new technologies and therapies that complement its existing offerings.

Notably, Novartis has made significant strides in gene therapy and cell-based treatments, positioning itself as a leader in cutting-edge therapeutic options. The company's global presence, coupled with its adaptive marketing strategies, strengthens its competitiveness in the market, enabling it to respond effectively to the changing dynamics and growing demands of the biopharmaceutical landscape worldwide.

Key Companies in the Biologic Therapy Market market include

Industry Developments

After losing Humira's exclusivity, AbbVie made a significant move into CAR-T cell and autoimmune medicines when it announced in June 30, 2025, that it would buy Capstan Therapeutics for up to $2.1 billion in cash.

Building on previous purchases, such as Gracell in late 2023, AstraZeneca agreed on March 17, 2025, to acquire EsoBiotec for up to $1 billion, including $425 million up front and $575 million in milestones, to strengthen its cancer and autoimmune cell therapy portfolio.

The incidence of chronic diseases, biotech innovation, and strategic industrial partnerships continue to be major growth drivers, according to experts' May 23, 2025, projections of the global biologics market, which are expected to expand at a rate of 10–12% through 2029.

Dr. Vinay Prasad, a well-known opponent of rapid approvals, was named director of the U.S. FDA's Center for Biologics Evaluation and Research on May 6, 2025. This appointment is expected to improve the standard of evidence for new biologic approvals globally.

The growing biosimilar landscape in immunology is further highlighted by the approval of Pyzchiva®, a ustekinumab biosimilar, by the European Commission in December 2024 and the marketing authorization of Usymro, another ustekinumab copycat, by the EMA's CHMP in June 2025.

Future Outlook

Biologic Therapy Market Future Outlook

The Biologic Therapy Market is projected to grow at a 3.49% CAGR from 2024 to 2035, driven by technological advancements, increasing chronic diseases, and rising healthcare expenditures.

New opportunities lie in:

Expansion of personalized biologic therapies for niche patient populations.Development of biosimilars to enhance market accessibility and affordability.Investment in digital health technologies to streamline biologic therapy management.

By 2035, the Biologic Therapy Market is expected to achieve substantial growth and innovation.

Market Segmentation

Biologic Therapy Market Type Outlook

Monoclonal Antibodies
Vaccines
Cell Therapy
Gene Therapy

Biologic Therapy Market End-user Outlook

Hospitals
Clinics
Home Healthcare

Biologic Therapy Market Application Outlook

Oncology
Autoimmune Diseases
Infectious Diseases
Cardiovascular Diseases

Biologic Therapy Market Route of Administration Outlook

Intravenous
Subcutaneous
Intramuscular

Report Scope

MARKET SIZE 2024	308.65(USD Billion)
MARKET SIZE 2025	319.42(USD Billion)
MARKET SIZE 2035	450.14(USD Billion)
COMPOUND ANNUAL GROWTH RATE (CAGR)	3.49% (2024 - 2035)
REPORT COVERAGE	Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
BASE YEAR	2024
Market Forecast Period	2025 - 2035
Historical Data	2019 - 2024
Market Forecast Units	USD Billion
Key Companies Profiled	Market analysis in progress
Segments Covered	Market segmentation analysis in progress
Key Market Opportunities	Advancements in personalized medicine enhance treatment efficacy in the Biologic Therapy Market.
Key Market Dynamics	Rising demand for personalized medicine drives innovation and competition in the biologic therapy market.
Countries Covered	North America, Europe, APAC, South America, MEA